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Cell proliferationa b s t r a c t
MicroRNA-107 (miR-107) has been demonstrated to regulate proliferation and apoptosis in many
types of cancers. Nevertheless, its biological function in gastric cancer remains largely unexplored.
Here, we found that the expression level of miR-107 was increased in gastric cancer in comparison
with the adjacent normal tissues. The enforced expression of miR-107 was able to promote cell pro-
liferation in NCI-N87 and AGS cells, while miR-107 antisense oligonucleotides (antisense miR-107)
blocked cell proliferation. At the molecular level, our results further revealed that expression of
FOXO1 was negatively regulated by miR-107. Therefore, the data reported here demonstrate that
miR-107 is an important regulator in gastric cancer, which will contribute to a better understanding
of the important mis-regulated miRNAs in gastric cancer.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Gastric cancer has become the fourth most common malignancy
and the second leading cause of death worldwide [1]. Multiple
studies have shown that gastric carcinoma arises via miss-
regulation of oncogenes and (or) tumor suppressors [2]. However,
the regulatory mechanisms involved in the initiation and progres-
sion of gastric cancer remains poorly understood. Therefore, iden-
tiﬁcation of critical carcinogenic pathways will help to discover
novel therapeutic targets for gastric cancer.
MicroRNA (miR), a class of small non-coding RNA molecule,
modulates expression of target genes through transcriptional or
post-transcriptional regulation [3]. Increasing studies have re-
vealed that miRNAs could function as either oncogenes or tumor
suppressors, and the mis-regulation of speciﬁc miRNAs is tightly
associated with cell proliferation, apoptosis, angiogenesis and
metastasis [4,5]. In gastric cancers, miR-107 was also shown to
promote tumor invasion and metastasis by targeting Dicer1 [6,7].
However, another study indicate that miR-107 induced cell cycle
G1 arrest and inhibited invasion by modulating CDK6 expression
[8]. These results indicate that the biology of miR-107 in tumor
is rather complicated and highly cell-type dependent. Therefore,
we aim to investigate the expression and roles of miR-107 in gas-
tric cancers in the present study.2. Materials and methods
2.1. Clinical tissue samples
Paired gastric adenocarcinoma tissues and adjacent non-tumor
gastric tissues were collected from routine therapeutic surgery at
our department. Our study was approved by the hospital institu-
tional review board. Written informed consent was obtained from
each patient.
2.2. Cell culture and reagents
Gastric cancer cell lines (NCI-N87 and AGS) were obtained from
American Type Culture Collection (Rockville, MD). Cells were cul-
ture in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Sigma. St.
Louis, MO) supplemented with 10% fetal bovine serum. Cultures
were maintained at 37 C in a humidiﬁed atmosphere with 5%
CO2. TNFa (10 ng/mL), IL-1b (2 ng/mL), and IL-6 (10 ng/mL) were
obtained from Sigma–Aldrich (USA).
2.3. Quantitative real-time PCR
Total RNA was harvested from tissue samples and cell lines
using the miRNA Isolation Kit (Ambion, USA). Expression of hsa-
miR-107 was assayed using Taqman MicroRNA Assay (Applied Bio-
systems). Quantitative real-time PCR was performed by using an
Applied Biosystems 7300 Real-time PCR System and a TaqMan Uni-
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tems) was used as an internal control.
2.4. Plasmid construction and transfection
For miR-107 expression plasmid, human miR-107 precursor
was cloned into pSilencer 4.1 (Ambion, Austin, TX) using the
following primers: Forward: 50-GCTACCAGTTACGCGATCTA-30;
Reverse: 50-CATCGGACTACTAGCAGAT-30. The negative control
plasmid consists of a scrambled sequence (Ambion). To inhibit
miR-107 function, an Ambion miRNA inhibitor for miR-107 was
used, along with the negative control. All the transfection experi-
ments were performed using Lipofectamine 2000 (Invitrogen, CA,
USA) following the manufacturer’s instructions.
2.5. Small interfering RNA and lentiviruses
p65 siRNA oligos were obtained from Dharmacon (Thermo
Scientiﬁc, Brookﬁeld, Wisconsin, USA). The siRNA sequence for
targeting p65 was as follows: 50-AAGCAUUAACUUCUCUGGAAA-30.As
negative control, a scramble siRNA oligo was used: 50-CAU-
ACGCUUAAUACUACGUCCA-30. The dominant negative IjBa was
subcloned into pLJM1 lentiviral vector. For lentivirus production,
293T cells were cotransfected with the lentiviral vector and pCMV
D8.91 and pMD VSV-G plasmids. Two days after transfection,
supernatant was collected, supplemented with 8 lg/mL polybrene,
and added for overnight incubation to freshly plated cells to be
transduced. 48 h after infection, the cells were selected in 2 lg/mL
puromycin.
2.6. BrdU cell proliferation assay
BrdU kits (Beyotime, Shanghai) were used to analyze the incor-
poration of BrdU during DNA synthesis following the manufac-
turer’s protocols. Values were determined at 450 nm in the
Spectra Max 190 ELISA reader (Molecular Devices, Sunnyvale,
CA). All the experiments were performed in triplicate.
2.7. Western blotting
Cells or tissues were harvested and lysed with ice-cold lysis buf-
fer containing 50 mM Tris–HCl, pH 6.8, 100 mM 2-ME, 2% w/v SDS
and 10% glycerol. After centrifugation, the supernatants were
quantiﬁed and separated by 10% SDS PAGE, transferred to NC
membrane (Amersham Bioscience, Buckinghamshire, UK). After
blocking with 10% non-fat milk in PBS, membranes were immuno-
blotted with antibodies, followed by HRP-linked secondaryFig. 1. Expression levels of miR-107 in gastric cancer tissues. (A) miR-107 expression wa
and pair-matched adjacent non-cancerous gastric tissues (Normal). Differences between
650 expression levels in cancer tissues with clinicopathological factors in patients withantibodies (Cell Signaling). The signals were detected by SuperSignal
West Pico Chemiluminescent Substrate kit (Pierce, Rockford, IL),
according to manufacturer’s protocols. Anti-phosphorylated
p65, anti-total p65, anti-IjBa, Anti-p27, anti-p21 and anti-Cyclin
D1 were purchased from Cellsignaling (USA). Anti-FOXO1 was
from Abcam (USA). Protein levels were normalized to total
GAPDH, using a rabbit polyclonal anti-GAPDH antibody (Santa
Cruz, USA).
2.8. Luciferase reporter assay
30-Untranslated region of FOXO1 was ampliﬁed into pMir-Re-
port vector (Ambion). Mutations of potential miR-107 binding sites
were obtained using the QuikChange site-directed mutagenesis Kit
(Stratagene). The pRL-SV40 vector of 10 ng (Promega, USA) carry-
ing the Renilla luciferase gene was used as an internal control to
normalize the transfection efﬁciency. Luciferase values were deter-
mined using the Dual-Luciferase Reporter Assay System (Promega).
2.9. Statistical analysis
Data are expressed as the mean ± S.E.M. from at least three sep-
arate experiments. Differences between groups were analyzed
using Student’s t-test and Chi-square test. A value of P < 0.05 was
considered statistically signiﬁcant.3. Results
3.1. Relationship of miR-107 expression levels and clinicopathological
factors in patients with gastric cancer
Firstly, expression level of miR-107 was determined using Taq-
Man real-time PCR in 65 pairs of human gastric cancer tissues and
pair-matched adjacent non-cancerous gastric tissues. As shown in
Fig. 1A, our results demonstrated that miR-107 was signiﬁcantly
up-regulated in gastric cancer tissues, compared with the adjacent
non-cancerous gastric tissues (Fig. 1A).
Next, miR-107 expression was evaluated with regards to the
clinicopathological characteristics of the patients. As shown in
Fig. 1B, the expression level of miR-107 was associated signiﬁ-
cantly with tumor size and differentiation (P < 0.05).
3.2. Identiﬁcation of miR-107 as a transcriptional target of NF-jB
Previous studies have shown that inﬂammatory responses are
responsible for the high rate of gastric cancer development [9].s determined by TaqMan real-time PCR in 65 pairs of human gastric cancer tissues
two groups were analyzed using Student’s t-test. ⁄⁄P < .01. (B) Relationship of miR-
gastric cancer. Differences between groups were analyzed using Chi-square test.
Fig. 2. NF-jB activation up-regulates miR-107 expression in gastric cancer cells. (A) Western blotting analysis of phosphorylated p65 (P-p65) and total p65 (T-p65) in gastric
cancer tissues and normal tissues. The amount of GAPDH was measured as a loading control. (B) Relative expression of miR-107 in NCI-N87 cells after exposure to TNFa
(10 ng/ml), IL-1b (20 ng/ml), IL-6 (50 ng/ml) or vehicle control (Ctrl) for 12 h. (C) Western blotting analysis of IjBa in NCI-N87 cells after transfection of dominant negative
IjBa (Dn-IjBa) or empty vector (Ctrl). (D) Relative expression of miR-107 in NCI-N87 cells treated with TNFa (10 ng/ml) for 12 h. Cells were pre-transfected with Dn-IjBa or
empty vector for 36 h. (E) Western blotting analysis of p65 in NCI-N87 cells after transfection of p65 siRNA oligos or scramble siRNA oligos (Ctrl). (F) Relative expression of
miR-107 in NCI-N87 cells treated with TNFa (10 ng/ml) for 12 h. Cells were pre-transfected with p65 siRNA oligos or scramble siRNA oligos for 36 h. Differences between two
groups were analyzed using Student’s t-test. ⁄⁄⁄P < .001.
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matory signaling, was highly elevated in gastric cancer tissues
(Fig. 2A). To investigate whether NF-jB mediated miR-107 overex-
pression, NCI-N87 cells were treated with several pro-inﬂamma-
tory cytokines. As shown in Fig. 2B, TNFa, IL-1b and IL-6
signiﬁcantly induced miR-107 mRNA levels. To determine whether
regulation of miR-107 was NF-jB dependent, NCI-N87cells were
transfected with lentiviruses expressing a dominant negative IjBa
(Fig. 2C), which could bind with p65 and inhibit its translocation
into the nucleus. As a result, inhibition of p65 activity by IjBa
inhibited the induction of miR-107 by TNFa (Fig. 2D). In addition,
knockdown of p65 by small interfering RNA (siRNA) also blocked
the induction of miR-107 by TNFa (Fig. 2E–F). To further explore
how NF-jB could regulate miR-107 expression, we examined
about 1 kb of the miR-107 promoter region using online computer
software TESS (http://www.cbil.upenn.edu/cgi-bin/tess/tess). A
consensus NF-jB site for potential binding by the NF-jB was iden-
tiﬁed at position 364 relative to the transcription start site of
miR-107. To determine whether this site was important for the
activation of the miR-107 promoter by NF-jB, we constructed
miR-107-luciferase reporter genes with or without the binding
site. We measured luciferase activity in cells transfected with the
reporter genes and NF-jB, respectively. As shown in Supplementary
Fig. 1A, p65 overexpression can activate the miR-107-500-luc
reporter that contains the binding site but not the miR-107-300-
luc reporter in which the NF-jB-binding site was deleted. This
activation was also diminished by point mutation of the NF-jB-
binding site (Supplementary Fig. 1B), indicating that this binding
site is essential for activation of the miR-107 promoter by NF-jB.Taken together, our results suggest that intrinsic inﬂammatory
pathways could be responsible for the up-regulation of miR-107
in gastric cancer tissues.
3.3. The effects of miR-107 on cell growth
In order to explore the effects of miR-107 on gastric cancer cell
growth, the miR-107 precursor was transfected into NCI-N87 or
AGS cells and the cell growth was examined. miR-107 precursor
was found to up-regulate miR-107 expression (Fig. 3A and B) and
signiﬁcantly inhibited proliferation in both cell lines (Fig. 3C and
D). Besides, miR-107-overexpressing cells had a signiﬁcantly lower
percentage of cells in the G1/G0 phase and increased percentage of
cells in the S phase, compared to negative control-transfected cells
(Fig. 3E and F).
3.4. miR-107 represses expression of the cell-cycle inhibitors p21Cip1
and p27Kip1 while increases expression of cell-cycle regulator cyclin
D1
As miR-107 promoted cell proliferation, we examined its func-
tions on expression of the genes which regulate the G1/S transi-
tion, including the CDK inhibitors p21Cip1 and p27Kip1 and the
CDK regulator Cyclin D1. Our results suggested that expression of
p21Cip1 and p27Kip1 were downregulated while cyclin D1 levels
were upregulated in miR-107-transfected cells, compared to NC-
transfected cells (Fig. 4A and B). Similar results were also observed
in AGS cell (Fig. 4C and D), further conﬁrming that miR-107 can
inﬂuence the proliferation of gastric cancer cells.
Fig. 3. Overexpression of miR-107 promotes gastric cancer cell proliferation. (A and B) Expression of miR-107 was determined in NCI-N87 (A) or AGS cells (B) after miR-107
precursor transfection compared to controls. (C and D) The cell proliferative potential (BrdU) was determined in NCI-N87 (C) or AGS (D) cells transfected with miR-107
precursor or negative control (Ctrl). A450 absorption was assayed after transfection for 24 h. (E and F) The cell cycle phase of NCI-N87 (E) or AGS cells (F) transfected with
miR-107 precursor or negative control (Ctrl) were analyzed by ﬂow cytometry. Cells were labeled for 15 min with PI and immediately analyzed by ﬂow cytometry.
Histograms represent the percentage of cells in each phase of the cell cycle (G0/G1, S and G2/M). Differences between two groups were analyzed using Student’s t-test.
⁄⁄P < .01; ⁄⁄⁄P < .001.
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cells
Next, miR-107 antisense was employed to investigate whether
its inhibition could block cell proliferation. As expected, miR-107
antisense increased the transcription of p21Cip1 and p27Kip1
and reduced the expression of Cyclin D1 (Fig. 5A–D). Moreover,
using the BrdU assay, we found that ectopic expression of
miR-107 antisense reduced the growth of NCI-N87 and AGS cancer
cells, compared to NC-transfected cells (Fig. 5E and F).
3.6. miR-107 directly targets the transcription factor FOXO1 in gastric
cancer cells
Previous studies have revealed that FOXO1 can transcriptionally
regulate genes related to the cell cycle, including p21Cip1, p27Kip1
and Cyclin D1 [10,11]. In parallel, we identiﬁed 18 putative human
miR-107 target genes using a bioinformatics approach (data not
shown), among which FOXO1 gene harbored a potential miR-107
binding site (Fig. 6A). Indeed, miR-107 overexpression led to a
reduction of luciferase activity when the reporter construct
contained the FOXO1 30-untranslated region (30 UTR) (Fig. 6B). Incontrast, mutation of the miR-107 binding site abrogated the
reduced luciferase expression (Fig. 6B). Moreover, miR-107 overex-
pression led to reduced FOXO1 protein expression in NCI-N87 and
AGS cells (Fig. 6C and D). Consistently, its inhibition resulted in an
increased expression of FOXO1 contents (Fig. 6E and F), further
indicating that FOXO1 is a target of miR-107 in gastric cancer cells.
4. Discussion
miR-107 was initially identiﬁed as a tumor suppressor in blad-
der, pancreatic, colon, head and neck cancer [12–15]. Its expression
was markedly reduced in bladder carcinoma compared to normal
bladder [12]. Overexpression of miR-107 in pancreatic cancer cells
repressed CDK6 levels and inhibited cell proliferation [13]. Besides,
forced expression of miR-107 inhibits colon cancer growth by sup-
pressing HIF-1b contents [14]. Moreover, miR-107 blocked cell
proliferation in head and neck squamous cell carcinoma (HNSCC)
by down-regulation of protein kinase Ce [15]. However, several
reports suggested that miR-107 may play an oncogenic role in
breast cancer [16,17]. Up-regulation of miR-107 was associated
with distant metastasis and poorer clinical outcome in breast
cancer. Overexpression of miR-107 in mammary epithelial cells
Fig. 4. miR-107 regulates expression of cell-cycle regulator. (A and B) Real-time PCR (A) and Western blotting (B) analysis of p21, p27 and Cyclin D1 in NCI-N87 cells
transfected with miR-107 precursor or negative control (Ctrl). (C and D) Real-time PCR (C) andWestern blotting (D) analysis of p21, p27 and Cyclin D1 in AGS cells transfected
with miR-107 precursor or negative control (Ctrl). Differences between two groups were analyzed using Student’s t-test. ⁄⁄P < .01; ⁄⁄⁄P < .001.
Fig. 5. miR-107 antisenses reduce the proliferation of gastric cancer cells. (A and B) Real-time PCR (A) and Western blotting (B) analysis of p21, p27 and Cyclin D1 in NCI-N87
cells transfected with miR-107 antisenses or negative control (Ctrl). (C and D) Real-time PCR (C) and Western blotting (D) analysis of p21, p27 and Cyclin D1 in AGS cells
transfected with miR-107 antisenses or negative control (Ctrl). (E and F) The cell proliferative potential (BrdU) was determined in NCI-N87 (E) or AGS (F) cells transfected with
miR-107 antisenses or negative control (Ctrl). A450 absorption was assayed after transfection for 24 h. Differences between two groups were analyzed using Student’s t-test.
⁄⁄P < .01; ⁄⁄⁄P < .001.
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Fig. 6. miR-107 negatively regulates FOXO1 expression in gastric cancer cells. (A) Computer prediction of miR-107 binding sites in the 30 UTRs of human genes. Potential
binding site was highlighted in bold. (B) Luciferase reporter assays in NCI-N87 cells. Cells were transfected with 100 ng of wild-type 30-UTR-reporter or mutant constructs
together with 50 nM of miR-107 precursor or miR-107 antisenses as indicated. (C and D) Western blotting analysis of FOXO1 in NCI-N87 (C) or AGS (D) cells transfected with
miR-107 precursor or negative control (Ctrl). (E and F) Western blotting analysis of FOXO1 in NCI-N87 (E) or AGS (F) cells transfected with miR-107 antisenses or negative
control (Ctrl). Differences between two groups were analyzed using Student’s t-test. ⁄⁄⁄P < .001.
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highly metastatic phenotype via regulation of Dicer1 [17].
Although the reason for this inconsistency is unclear, the role of
miR-107 in the cell proliferation is cell or tissue-speciﬁc, which
may dependent on cellular context or different downstream target
genes. Therefore, the precise roles and mechanisms of miR-107 in
tumors need to be further investigated using other models, such as
tissue-speciﬁc miR-107 knockout mice.
In gastric cancer, the down-regulation of FOXO1 in tumor cells
was observed in most of gastric carcinoma cases, and was found to
be positively associated with higher microvessel area [18,19].
Moreover, phosphorylated FOXO1 expression was positively corre-
lated with the expressions of several angiogenesis-related proteins,
including hypoxia inducible factor-1a, vessel endothelial growth
factor, phosphorylated protein kinase B [18,19]. However, the
reasons why FOXO is downregulated in cancer cells are poorly
characterized. Thus, our results suggest that microRNA may
represent an alternative mechanism to regulate FOXO1 in gastric
cancers. It has been demonstrated that FOXO1 expression is
regulated by several microRNAs, such as miR-223, miR-182,
miR-139, miR-96 and miR-370 [20–24]. Of these, some microRNAs
may be dysregulated in gastric cancer, such as miR-223, miR-139
and miR-370 [25–27]. Although the reason why multiple
microRNAs regulate a single mRNA remains unexplored now, we
speculate that dys-regulation of these miRNAs could contribute
to tumor initiation and (or) progression, at least in part, through
down-regulation of FOXO1.
In summary, we found that up-regulation of miR-107 correlated
with clinical progression and increased gastric cancer cell prolifer-
ation by targeting FOXO1. Understanding the regulatory mecha-
nism by miR-107 may advance our knowledge of gastric cancer
biology, which will help to identify novel gene therapies for the
treatment of gastric cancer.
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